Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cycloastragenol is a triterpenoid saponin aglycone derived from Astragalus species, particularly *Astragalus membranaceus*, a plant widely used in Traditional Chinese Medicine. It is recognized for its potential anti-aging properties and broad pharmacological effects. Cycloastragenol acts primarily as a telomerase activator—promoting the maintenance and elongation of telomeres—which are protective caps at the ends of chromosomes associated with cellular aging. Additional reported activities include antioxidative and anti-inflammatory effects, improvement of lipid metabolism, enhancement of immune function (notably in CD8+ T lymphocytes), promotion of wound repair, inhibition of endoplasmic reticulum stress-associated inflammasome activation (TXNIP/NLRP3), and possible neuroprotective actions such as axon regeneration after spinal cord injury. Cycloastragenol is efficiently absorbed via passive diffusion through the intestinal epithelium but undergoes significant first-pass hepatic metabolism that may limit its oral bioavailability[1][2][3][4][7][8]. Clinical research suggests it is relatively safe within certain dose ranges; however, herb-drug interactions and long-term safety require further study.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cycloastragenol.